Bowel cancer rates after colonoscopy vary by provider

November 13, 2019

A colonoscopy is the main test used to detect bowel cancer, but like most tests, it is not always 100% accurate and cancers can be missed.

New research led by the University of Leeds looked at the number of patients whose colonoscopy found no evidence of bowel cancer, but who were subsequently diagnosed with the disease.

They found that overall the rate of these post-colonoscopy bowel cancers decreased in England. However, they found that the rates of these potentially missed cancers were lower for colonoscopies performed by the NHS than those performed by independent providers on behalf of the NHS.

Co-author Professor Eva Morris, from the University of Leeds, said: "Overall we found the proportion of people whose bowel cancer is being missed by a colonoscopy procedure has declined, meaning that our diagnostic services are getting more and more accurate.

"However, this study reveals wide variation in the accuracy of colonoscopy tests depending on the provider, meaning that some cancers are still being missed. This urgently needs to be addressed to ensure we are detecting cancer cases as early as possible."

Amongst people diagnosed with bowel cancer who had a colonoscopy within the NHS Bowel Cancer Screening Programme, 3.6% could potentially have been diagnosed at an earlier time point. In contrast, if a person's colonoscopy was undertaken by an NHS commissioned independent provider 9.3% could potentially have been diagnosed sooner.

The researchers say that if the lower rate had been achieved over the entire nine-year study period, more than 3,900 cases of colorectal cancer could have been prevented or diagnosed earlier.

Bowel cancer, also called colorectal cancer, is a major public health problem in the UK, with over 40,000 new cases diagnosed and 16,000 deaths each year.

In their new study published in The BMJ, scientists assessed more than 120,000 people diagnosed with bowel cancer in England between 2005 and 2013. They looked at the number of people who had previously received a colonoscopy, from six months to three years earlier, whose cancer could potentially have been spotted earlier.

Overall, they found that the rates of post-colonoscopy bowel cancer have significantly reduced and are now amongst the lowest rates seen worldwide, reflecting the high quality of colonoscopy for bowel cancer in England.

Amongst those diagnosed with bowel cancer, the proportion of people who had received a colonoscopy within the previous three years who could potentially have been diagnosed sooner declined from 9.0% in 2005 to 6.5% in 2013.

However, what needs addressing is the variation between providers with some having much lower, and some much higher rates.

The British Society of Gastroenterology say post-colonoscopy bowel cancers should be used as a benchmark for the quality of a colonoscopy service.

Lead author Dr Nick Burr, from the University of Leeds, said: "We need a targeted improvement programme to reduce this variation in the quality of colonoscopy procedures between providers.

"Ensuring we have uniform high standards for colonoscopies will help us reduce the number of post-colonoscopy cancers further, and improve mortality from this preventable disease."

Rates of post-colonoscopy bowel cancer diagnosis were higher among women, people aged 80 or over, and those with inflammatory bowel disease.

The lowest rates were achieved by accredited bowel cancer screening providers and some of the higher rates by private providers working on behalf of the NHS. By reducing this variation, and lowering rates further, many cancers could be diagnosed at an earlier stage or even prevented, say the researchers.

Bowel cancer survivor John Barnes said: "Many people undergoing colonoscopy tests aren't aware that cancers or their precursors can be left undetected. The results of this study are both heartening and concerning.

"Clearly when strict colonoscopy standards are applied, as they are in the NHS Bowel Cancer Screening Programme, quality can be improved and lives can potentially be saved.

"This research is an excellent example of how intelligence generated through healthcare data can have a real-world impact and benefit patients."

Co-author Roland Valori, a Consultant Gastroenterologist in the NHS, said: "This research is good news - it shows that the significant effort by the NHS to improve the quality of colonoscopies is working, and the rates of missed cancers are coming down.

"However, we are seeing unacceptable variation in post colonoscopy bowel cancers between providers in the English NHS and this variation in quality needs to be addressed urgently."

This is an observational study so it can't establish cause, and the researchers point to some limitations in the data, which may have affected the accuracy of the calculations.

Nevertheless, they say this is a large, nationally representative study, and the variation between providers remained after further analyses, suggesting that the findings are robust.
The research was funded by the Bobby Moore Fund, Cancer Research UK, Yorkshire Cancer Research, and Crohn's and Colitis UK.

University of Leeds

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to